Impact of effective platelet–rich plasma in treatment for knee osteoarthritis

Abstract

Background

Platelet-rich plasma (PRP) injections have become an intriguing treatment option for osteoarthritis (OA), particularly OA of the knee. There is a paucity of high-level evidence that is comparable, cohort specific, dose controlled injection protocol controlled and double-blinded.

Purpose

To assess the safety and efficacy of platelet-rich plasma (PRP) for knee OA treatment through feasibility trial regulated by the US Food and Drug Administration (FDA).

Study design

A prospective observational study.

Method

In accordance with FDA protocol, patient selection was based on strict inclusion/exclusion criteria; 30patients were screened and included in the study. These patients were received platelet-rich plasma (PRP).Western Ontario and McMaster universities osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS) scores served as the primary efficacy outcome measures. Patients were followed for 3 months. The present study carried out in Gandhi Medical College and Hospital, Telangana, India to study the Impact of PRP in the treatment of knee osteoarthritis.

Results

No adverse events were reported for PRP administration. Furthermore, the results demonstrated no statistically significant difference in baseline WOMAC, VASscore. However; WOMAC scores at 1 week were significantly decreased compared with baseline scores, and the scores for this group remained significantly lower throughout the study duration. At the study conclusion (3 months), improved overall WOMAC scores by 80% from their baseline score.

Conclusion

PRP is safe and provides quantifiable benefits for pain relief and functional improvement with regard to knee Osteoarthritis. No adverse events were reported for PRP administration. After 3 months, WOMAC scores improved by 80% from their baseline score. Other joints affected with OA may also benefit from this treatment.